James Evanson, MD
Nephrology · Evansville, INNPI 1093715435
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Bayer accounts for 81.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $10,491 and has fallen 51.6% since, to $5,073 in 2025. Among nephrology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $89.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$17K
- AstraZeneca$753
- Mallinckrodt Hospital Products Inc.$740
- Otsuka America Pharmaceutical, Inc.$520
- Travere Therapeutics, Inc.$256
- Akebia Therapeutics Inc$242
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,5397%
- Speaking & faculty fees$11,12852%
- Travel & lodging$3,00514%
- Food & beverage$5,33825%
- Education$2971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 53 | $17,262 |
| AstraZeneca | 37 | $753 |
| Mallinckrodt Hospital Products Inc. | 27 | $740 |
| Otsuka America Pharmaceutical, Inc. | 24 | $520 |
| Travere Therapeutics, Inc. | 11 | $256 |
| Akebia Therapeutics Inc | 14 | $242 |
| Calliditas Therapeutics US Inc. | 11 | $234 |
| ANI Pharmaceuticals, Inc. | 11 | $212 |
| Vifor Pharma, Inc. | 11 | $193 |
| Amgen | 7 | $141 |
| Ardelyx, Inc. | 4 | $121 |
| Johnson & Johnson | 2 | $112 |
| Novartis | 6 | $111 |
| Kyowa Kirin, Inc. | 2 | $94 |
| Boehringer Ingelheim | 5 | $91 |
| GSK | 4 | $63 |
| Fresenius USA Marketing, Inc. | 3 | $63 |
| Lundbeck LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,308 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 33 | $656,701 |
| KerendiaFinerenone | 126 | $118,637 |
| VelphoroSucroferric Oxyhydroxide | 23 | $81,980 |
| FarxigaDapagliflozin Propanediol | 61 | $53,912 |
| AuryxiaFerric Citrate | 20 | $15,710 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $12,500 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $10,441 |
| Sevelamer Carbonate | 37 | $5,557 |
| ClinisolParenteral Amino Acid 15% No.5 | 20 | $3,260 |
| Potassium Chloride | 43 | $1,094 |
| Bumetanide | 21 | $1,062 |
| Torsemide | 67 | $989 |
| Candesartan Cilexetil | 12 | $779 |
| Losartan Potassium | 119 | $771 |
| Tamsulosin Hcl | 80 | $752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $520 | $656,70133 claims |
| BayerKerendia | $17,262 | $118,637126 claims |
| Fresenius USA Marketing, Inc.Velphoro | $63 | $81,98023 claims |
| AstraZenecaFarxiga, Lokelma | $753 | $66,41375 claims |
| Akebia Therapeutics IncAuryxia | $242 | $15,71020 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $212 | $22714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 nephrology providers in Indiana.
Other nephrology in Evansville
- Narothama Reddy AeddulaEvansville$125K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Jorge DiegoShelbyville$81K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.